Amylyx Pharmaceuticals, Inc. Common Stock (AMLX)
NASDAQ
Closed
Aug 24, 2026
Day's Range
37.4552 wk Range
8.47Overview - AMLX - Amylyx Pharmaceuticals, Inc. Common Stock
Key Statistics
Valuation
Enterprise Value
4.06B
P/E (Trailing)
‪2.53‬
P/E (Forward)
‪-33.05‬
PEG Ratio
‪-0.16‬
Price / Book
‪17.76‬
EV / EBITDA
‪-25.11‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪0.00%‬
Return on Assets
‪-44.13%‬
Return on Equity
‪-74.73%‬
Ownership
Shares Outstanding
111.36M
Float
83.52M
Short % of Shares Outstanding
‪15.56%‬
Held by Insiders
‪7.10%‬
Held by Institutions
‪93.78%‬
Price stats
Beta
‪-0.20‬
50-Day Avg
‪20.27‬
200-Day Avg
‪15.74‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
11 analysts
Average price target
‪$ 27.50‬Shariah Compliance
Report Date: Feb 20, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - AMLX - Amylyx Pharmaceuticals, Inc. Common Stock
Peers - AMLX - Amylyx Pharmaceuticals, Inc. Common Stock
Peer Comparison
Compared with companies in Drug Manufacturers - Specialty & Generic listed on NASDAQ.
- AMLXNASDAQAmylyx Pharmaceuticals, Inc. Common Stock4.41BMarket Cap+76.55%52-week change2.54P/E (Trailing)‪0.00%‬Profit Margin
- NBIXNASDAQNeurocrine Biosciences Inc.15.50BMarket Cap+12.18%52-week change22.34P/E (Trailing)‪20.91%‬Profit Margin
- ALALKSNASDAQAlkermes plc8.10BMarket Cap+40.00%52-week change127.18P/E (Trailing)‪3.96%‬Profit Margin
- LNTHNASDAQLantheus Holdings, Inc.6.52BMarket Cap+43.82%52-week change23.92P/E (Trailing)‪17.69%‬Profit Margin
- AMRXNASDAQAmneal Pharmaceuticals Inc.6.23BMarket Cap+48.19%52-week change37.60P/E (Trailing)‪5.04%‬Profit Margin
- KNKNSANASDAQKiniksa Pharmaceuticals International, plc6.16BMarket Cap+58.19%52-week change79.83P/E (Trailing)‪9.59%‬Profit Margin
- ALMNASDAQAlmonty Industries Inc.5.33BMarket Cap+76.82%52-week change84.14P/E (Trailing)‪125.23%‬Profit Margin
Profile Summary - AMLX - Amylyx Pharmaceuticals, Inc. Common Stock
About
Amylyx Pharmaceuticals, Inc. Common Stock represents ownership in a clinical-stage biopharmaceutical company dedicated to developing investigational therapies for neurodegenerative diseases and endocrine conditions. The company focuses on advancing its pipeline, including avexitide, a first-in-class GLP-1 receptor…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
